Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
- Resource Type
- Article
- Source
- BMJ Open; Jul2020, Vol. 10 Issue 7, p1-6, 6p
- Subject
- Language
- ISSN
- 20446055